Public Health England and NanoViricides sign testing agreement

Published: 9-Jul-2013
Research & Development

Agreement concerns testing of various nanoviricides against specific viruses of current concern


NanoViricides has signed a 'confidential disclosure agreement' with Public Health England (PHE), that will allow the scientists at Public Health England to develop a specific proposal for the testing of different nanoviricides, such as FluCide, against viruses of 'mutual interest' to both organisations.

More specifically, the first two viruses of mutual interest are H7N9, the influenza virus now circulating in China, as well as the latest version of the coronavirus, now circulating in the Middle East and referred to as the MERS virus. This virus is similar to the SARS virus that infected 8,000 people and killed approximately 800 people 10 years ago. Both H7N9 and the MERS CoV (coronavirus) have extremely high case fatality rates.

Testing of nanoviricides antiviral drug candidates will be performed in a BSL3/4 facility at PHE. BSL3/4 facilities are designed to contain and enable the safe handling of organisms that can pose a significant threat to health.

NanoViricides is a development stage company that is creating special purpose nanomaterials for viral therapy. Its novel nanoviricide class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. The company is developing drugs against a number of viral diseases including H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others.

PHE works with national and local government, industry and the UK National Health Service (NHS) to protect and improve the nation's health and support healthier choices and will be addressing inequalities by focusing on removing barriers to good health.

  • Companies:
  • Public Health England
See more

You may also like

Media

Needle-free vaccine collaboration for emergent threat pathogens

Read more
Enesi Pharma has entered a research and development collaboration with Public Health England

Trending Articles

  1. Thermo Fisher Scientific reveals MagMax Sequential DNA/RNA Kit to advance blood cancer research The kit combines DNA and RNA isolation chemistries into a single kit, simplifying sample extraction for a broad range of downstream molecular applications
  2. Thermo Fisher Scientific officially opens US oral solid dose testing and R&D facility The company's further expansion in the Bend, Oregon area will assist its pharmaceutical clients in the early development of oral solid dosage (OSD) forms
  3. BioMarin Pharmaceutical expands Cork targeted therapy manufacturing facility with new lab The Irish facility is responsible for the development and commercialisation of therapies that address genetic conditions, and this expansion will allow the company to enhance its approved medicine production capacity
  4. Medac and chiron develop organ-on chip tech for animal free drug testing The companies aim to develop an animal-free pharmaceutical testing method that utilises organ-on chip technology, and will be used in rheumatoid arthritis drug testing
  5. You need to be a subscriber to read this article.
    Click here to find out more.
    Parenteral preparations: formulation challenges Parenteral preparations are defined as solutions, suspensions, emulsions for injection or infusion, powders for injection or infusion, gels for injection and implants. They are sterile preparations that are administrated directly into the systemic circulation of humans or animals

Upcoming event

EMPQ Essentials and Real-World Strategies for Successful Cleanroom Qualifications

16 January 2025 | Virtual See all

You may also like

Media

Needle-free vaccine collaboration for emergent threat pathogens

Enesi Pharma has entered a research and development collaboration with Public Health England
Research & Development

Consortium wins £1m grant to develop in the field test for Ebola

Public Health England (PHE) scientists will head the group researching the test
Research & Development

Kymab and the Wellcome Trust initiate Ebola project

Drug discovery partnership to produce an antibody based medicine to fight Ebola infection
Research & Development

Opinion: Staring into the abyss

The price to overcome the problem of antibiotic resistance will be high
Regulatory

HPA-led consortium wins €6m EU contract

To develop exercises and training to deal with cross-border health threats
Drug Delivery

HPA awarded £4m contract by US government to develop anthrax vaccine

Will be delivered by an intra-nasal spray device instead of an injection
Research & Development

Scientists closer to breakthrough in Meningitis B vaccine component

Studied Neisserial Heparin Binding Antigen to understand its structure
Subscribe now